Prothena Corp. Plc (PRTA)

9.40
NASDAQ : Health Technology
Prev Close 9.96
Day Low/High 9.37 / 9.98
52 Wk Low/High 8.63 / 15.91
Avg Volume 286.80K
Exchange NASDAQ
Shares Outstanding 39.87M
Market Cap 397.06M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Why Prothena (PRTA) Stock Is Up Today

Why Prothena (PRTA) Stock Is Up Today

Prothena (PRTA) shares are up following the publishing of an abstract touting its AL amyloidosis treatment

Why Prothena (PRTA) Hit an All-Time High Today

Why Prothena (PRTA) Hit an All-Time High Today

Prothena (PRTA) surged more than 25% and hit an all-time high of $47.48 on Wednesday, one day after the biotech company announced it would present clinical data at the XIV International Symposium on Amyloidosis in Indianapolis from April 27 to May 1. In the wake of this news, RBC Capital Markets increased its target price on Prothena to $52 from $38 and maintained its "outperform" rating. The firm contends that the ISA abstract title indicates that the company's NEOD001 drug produced early cardiac responses in amyloidosis patients. The firm believes this outcome surpasses analysts' estimates and indicates the drug could be worth more than $500 million.

Ratings Changes Today

Upgrades: CCJ, CSH, ENPH, EQR, GES, NFX, TDG, UPL Downgrades: ARCP, ARR, AUY, FUR, MAYS, VRTB Initiations: ENSV, PRTA Read on to get TheStreet Quant Ratings' detailed report:

3 Big-Volume Biotech Stocks to Watch

3 Big-Volume Biotech Stocks to Watch

Keep these biotech stocks rising on unusual volume on your radar.

4 Stocks Spiking on Big Volume

4 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Prothena Reports First Quarter Financial Results

Prothena Reports First Quarter Financial Results

Phase 1 Clinical Trial Initiated in April for NEOD001 in AL Amyloidosis Patients

First Patient Dosed In Phase I Study Of Prothena's Therapeutic Antibody For Treatment Of AL Amyloidosis

First Patient Dosed In Phase I Study Of Prothena's Therapeutic Antibody For Treatment Of AL Amyloidosis

NEOD001 Enters Clinic With Orphan Designation and Potential to Meet Significant Unmet Need

TheStreet Quant Rating: D (Sell)